Ironwood Pharmaceuticals (NASDAQ:IRWD) Trading 11.1% Higher – What’s Next?

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) shares shot up 11.1% on Monday . The company traded as high as $3.87 and last traded at $3.81. 560,367 shares were traded during trading, a decline of 80% from the average session volume of 2,832,662 shares. The stock had previously closed at $3.43.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Leerink Partnrs raised shares of Ironwood Pharmaceuticals to a “hold” rating in a research note on Monday, September 9th. StockNews.com lowered Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, November 12th. Finally, Leerink Partners started coverage on Ironwood Pharmaceuticals in a research report on Monday, September 9th. They set a “market perform” rating and a $5.00 price target for the company. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $10.40.

Ironwood Pharmaceuticals Stock Down 6.5 %

The business’s fifty day moving average is $4.05 and its two-hundred day moving average is $5.04. The stock has a market cap of $595.31 million, a price-to-earnings ratio of -124.00 and a beta of 0.41.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.07). The company had revenue of $91.60 million for the quarter, compared to analysts’ expectations of $91.22 million. Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%. The firm’s revenue was down 19.4% compared to the same quarter last year. During the same period in the prior year, the company posted $0.12 EPS. As a group, sell-side analysts expect that Ironwood Pharmaceuticals, Inc. will post 0.08 earnings per share for the current year.

Insider Activity

In related news, CFO Sravan Kumar Emany sold 11,001 shares of the business’s stock in a transaction on Monday, November 18th. The shares were sold at an average price of $4.08, for a total transaction of $44,884.08. Following the completion of the transaction, the chief financial officer now owns 309,572 shares in the company, valued at approximately $1,263,053.76. The trade was a 3.43 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 12.90% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. CWM LLC boosted its holdings in shares of Ironwood Pharmaceuticals by 55.1% in the 2nd quarter. CWM LLC now owns 6,600 shares of the biotechnology company’s stock valued at $43,000 after buying an additional 2,345 shares in the last quarter. Louisiana State Employees Retirement System boosted its stake in Ironwood Pharmaceuticals by 3.5% in the second quarter. Louisiana State Employees Retirement System now owns 70,400 shares of the biotechnology company’s stock valued at $459,000 after acquiring an additional 2,400 shares in the last quarter. SummerHaven Investment Management LLC grew its holdings in shares of Ironwood Pharmaceuticals by 3.6% during the second quarter. SummerHaven Investment Management LLC now owns 72,030 shares of the biotechnology company’s stock worth $470,000 after purchasing an additional 2,491 shares during the last quarter. Rhumbline Advisers increased its position in shares of Ironwood Pharmaceuticals by 0.7% during the second quarter. Rhumbline Advisers now owns 365,701 shares of the biotechnology company’s stock worth $2,384,000 after purchasing an additional 2,577 shares in the last quarter. Finally, KBC Group NV lifted its holdings in shares of Ironwood Pharmaceuticals by 59.3% in the 3rd quarter. KBC Group NV now owns 8,593 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 3,198 shares during the last quarter.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.